|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123724 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-29 10:53:09 |
|
注册时间: Date of Registration: |
2026-04-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国助听队列 |
|
Public title: |
China Auditory Intervention Cohort |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国助听队列 |
|
Scientific title: |
China Auditory Intervention Cohort |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙宇 |
研究负责人: |
孙宇 |
|
Applicant: |
Yu Sun |
Study leader: |
Yu Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 27 8535 0922 |
研究负责人电话: Study leader's telephone: |
+86 27 8535 0922 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sunyu@hust.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
sunyu@hust.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市江汉区解放大道1277号协和医院 |
研究负责人通讯地址: |
湖北省武汉市解放大道1277号 |
|
Applicant address: |
NO.1277 Jiefang Avenue, Wuhan, Hubei |
Study leader's address: |
NO.1277 Jiefang Avenue, Wuhan, Hubei |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Applicant's institution: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Affiliation of the Leader: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2026]伦审字(0279)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属协和医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Union Hospital of Tongji Medical College Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-26 00:00:00 |
||
|
伦理委员会联系人: |
褚圆圆 |
||
|
Contact Name of the ethic committee: |
Chu YuanYuan |
||
|
伦理委员会联系地址: |
湖北省武汉市解放大道1277号 |
||
|
Contact Address of the ethic committee: |
NO.1277 Jiefang Avenue, Wuhan, Hubei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 85726375 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
994877373@qq.com |
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属协和医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市解放大道1277号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
NO.1277 Jiefang Avenue, Wuhan, Hubei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised funds for research projects |
||||||||||||||||||||||
|
Target disease: |
Bilateral sensorineural hearing loss, bilateral mixed hearing loss |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究为多中心、前瞻性、观察性队列研究,以首次验配助听器的老年听障人群(≥60 岁)与听障儿童(6 个月~6 岁)为研究对象,通过至少 5 年的纵向随访,系统开展以下研究目的。 核心目的:明确助听器长期使用模式(佩戴时长、依从性、设备参数、使用效果)与使用者核心功能结局纵向变化轨迹的关联,量化助听器使用对老年人群认知功能、儿童人群言语语言能力发展的真实长期效应。 老年队列具体目的 1. 探究助听器日均佩戴时长、使用依从性与MoCA 认知评分长期变化的剂量–效应关系。 2. 分析助听器使用对老年人听觉相关生活质量、情绪状态、睡眠质量、社会参与、整体健康等次要结局的长期影响。 3. 识别基线听力损失程度、病因、人口学特征等因素对助听器–认知保护效应的修饰作用。 儿童队列具体目的 1. 揭示助听器佩戴依从性、干预年龄、补偿效果与标准化言语语言能力长期发展轨迹的关联。 2. 评估助听器使用对听障儿童认知发育、社会情绪适应、生活质量、学业表现等多维发育结局的持续影响。 3. 明确听力损失程度、干预时机、家庭与康复环境等因素对儿童言语认知发展的交互作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
This is a multicenter, prospective, observational cohort study enrolling first-time hearing aid users: elderly (>=60 years) and children (6 months–6 years), with >=5 years of follow-up. Core Objective: To identify the long-term association between hearing aid use patterns and core functional outcomes, and quantify real effects on elderly cognition and children’s speech ability. Elderly Cohort: 1. Explore dose–response between daily use, adherence and MoCA scores; 2. Analyze long-term effects on quality of life, emotion, sleep and social participation; 3. Identify modifiers of cognitive protection. Pediatric Cohort: 1. Reveal links between adherence, intervention age, amplification efficacy and speech development; 2. Evaluate impacts on cognition, socioemotional function, quality of life and academic performance; 3. Clarify interactive effects on speech-cognitive development. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
老年人群队列: 1.年龄 ≥ 60周岁。 2.经纯音测听确诊为双侧感音神经性或混合性听力损失,且符合助听器验配指征。 3.首次验配助听器。 4.意识清楚,具备基本的读写能力,能与研究人员有效沟通。 5.自愿参加并签署书面知情同意书。 儿童人群队列: 1.年龄 6个月至6周岁。 2.经客观和/或行为测听确诊为双侧感音神经性或混合性听力损失,并符合助听器验配指征。 3.首次验配助听器。 4.主要监护人具备基本的读写与沟通能力,能理解研究内容并配合完成问卷。 5.主要监护人自愿参加并代表儿童签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Older Adults Cohort: 1. Age ≥ 60 years. 2. Diagnosed with bilateral sensorineural or mixed hearing loss by pure-tone audiometry and meeting the indication for hearing aid fitting. 3. First-time hearing aid fitting. 4. Clear consciousness, possessing basic literacy skills, and able to communicate effectively with researchers. 5. Voluntary participation and provision of written informed consent. Pediatric Cohort: 1. Aged 6 months to 6 years. 2. Diagnosed with bilateral sensorineural or mixed hearing loss by objective and/or behavioral audiometry and meeting the indication for hearing aid fitting. 3. First-time hearing aid fitting. 4. The primary guardian possesses basic literacy and communication skills, can understand the study content, and can cooperate in completing questionnaires. 5. The primary guardian voluntarily participates and provides written informed consent on behalf of the child. |
||||||||||||||||||||||
|
排除标准: |
老年人群队列: 1.确诊患有痴呆、阿尔茨海默病、帕金森病、精神分裂症或其他严重影响认知功能评估的神经系统或精神疾病。 2.有严重的、未矫正的视力障碍或肢体活动障碍,导致无法完成纸质量表评估或计算机化测试。 3.患有严重的、不稳定的躯体疾病(如晚期恶性肿瘤、严重心衰、肾衰等),经研究者判断预期生存期<5年或无法完成随访。 4.计划在未来5年内永久迁出研究所在城市,无法完成定期随访。 5.过去12个月内经历可能严重影响心理状态的重大负性生活事件(如丧偶、重大家庭变故),经研究者评估不宜入组。 儿童人群队列: 1.确诊患有智力障碍、自闭症谱系障碍、脑性瘫痪或其他已知的、严重影响发育评估的神经系统疾病或遗传综合征。 2.伴有重度至极重度视力障碍(即使矫正后),严重影响其进行基于视觉的评估或日常活动。 3.患有严重的、不稳定的全身性疾病(如先天性心脏病术后不稳定、代谢性疾病未控制等),经研究者判断可能影响随访或发育评估。 4.计划在未来5年内永久迁出研究所在城市,无法完成定期随访。 5.主要监护人存在精神或心理疾病,无法稳定配合完成研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Older Adults Cohort: 1. Diagnosed with dementia, Alzheimer’s disease, Parkinson’s disease, schizophrenia, or other neurological or psychiatric conditions that severely affect cognitive function assessment. 2. Severe, uncorrected visual impairment or physical mobility impairment that prevents completion of paper-based scale assessments or computerized tests. 3. Severe, unstable systemic diseases, with an expected survival of <5 years or inability to complete follow-up, as judged by the investigator. 4. Planning to permanently relocate out of the study city within the next 5 years, making regular follow-up impossible. 5. Experienced major negative life events in the past 12 months that may severely affect psychological state, and deemed unsuitable for enrollment by the investigator. Pediatric Cohort: 1. Diagnosed with intellectual disability, autism spectrum disorder, cerebral palsy, or other known neurological disorders or genetic syndromes that severely affect developmental assessment. 2. Accompanied by severe to profound visual impairment (even after correction), seriously affecting visual-based assessments or daily activities. 3. Suffering from severe, unstable systemic diseases, which may affect follow-up or developmental assessment, as judged by the investigator. 4. Planning to permanently relocate out of the study city within the next 5 years, making regular follow-up impossible. 5. The primary guardian has a mental or psychological disorder and cannot stably cooperate to complete the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-01 00:00:00至 To 2032-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-01 00:00:00 至 To 2027-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Data not to be shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1. 病例记录表 统一设计并使用标准化病例记录表,分别制定老年受试者与儿童受试者专用版本,用于完整记录基线信息、听力评估、助听器使用情况、认知 / 言语发育评估、随访数据、不良事件及各类量表评分,确保数据采集规范、完整、可溯源。 2. 电子数据采集和管理系统 采用电子数据采集系统进行数据录入、核查与管理。研究人员通过移动终端现场直接录入数据,系统内置逻辑核查、必填项校验与异常值提醒功能,保障数据准确性。所有数据实时上传至加密服务器,由专人负责数据审核、清理与锁定。数据完成清理并锁定后不再修改,纸质原始资料与电子数据双重归档保存,确保数据安全、完整与可追溯。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Case Record Form: Standardized case record forms will be uniformly designed and applied, with dedicated versions for elderly and pediatric subjects. These forms are used to comprehensively document baseline information, hearing assessments, hearing aid usage, cognitive/speech developmental evaluations, follow-up data, adverse events, and scores of various scales, ensuring standardized, complete, and traceable data collection.2. Electronic Data Capture: SystemAn electronic data capture system will be adopted for data entry, verification, and management. Researchers directly enter data on-site via mobile devices. The system is equipped with built-in logical checks, mandatory field validation, and outlier alerts to ensure data accuracy. All data are uploaded to encrypted servers in real time and reviewed, cleaned, and locked by dedicated personnel. Once cleaned and locked, data will remain unchanged. Both paper source documents and electronic data will be archived to ensure data security, integrity, and traceability. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |